This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Opsona Therapeutics Ltd.
Drug Names(s): OPN-305
Description: OPN-305 is a monoclonal antibody inhibitor of Toll-like-receptor-2 (TLR-2).
Deal Structure: OPN-305 was originally developed by Opsona.
In February 2009, Opsona entered into an agreement with Lonza. Lonza will provide process development and cGMP manufacturing services for preclinical and Phase I studies using Lonzas GS Gene Expression System.
Additional information available to subscribers only: